Evinacumab with or without lipoprotein apheresis in homozygous familial hypercholesterolaemia
This study demonstrated considerable benefit of evinacumab for individuals with HoFH, with or without concurrent LA. Evinacumab appeared to lessen LA burden for some individuals. This analysis suggests that LA and evinacumab can be combined without compromising efficacy or safety.
Authors
- Xue-Qiao Zhao (ORCID: https://orcid.org/0000-0001-7713-6369)
- Alpana Waldron
- A. Wiegman
- Patrick M Moriarty
- Richard Godin
- Daniel Gaudet
- Robert S Rosenson
- Robert Pordy
- Frederick J Raal
Institutions
- Université du Québec à Chicoutimi (CA)
- Regeneron (United States) (US)
- University of the Witwatersrand (ZA)
- Mount Sinai Hospital (US)
- Amsterdam Neuroscience (NL)
- University of Kansas Medical Center (US)
- Institute for Atherosclerosis Research (RU)
- University of Amsterdam (NL)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- European Journal of Preventive Cardiology
- Published
- 2026-03-26
- DOI
- https://doi.org/10.1093/eurjpc/zwag182
- Primary Topic
- Lipid metabolism and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00